VirX is the first line of defense against airborne viruses.
VirX is a nitric oxide nasal spray formulated with an exclusive formula. The trace amount of nitric oxide released during use can block the invasion of viruses and kill 99.9%* viruses in the upper respiratory tract within 2 minutes. The product is a topical, non-systemic nasal spray synthesized from a compound widely used in food.
Among them, nitric oxide is a natural nano-molecule, and its resistance to various viruses, including new viruses, has been scientifically certified.
Developed by SaNOtize Research and Development Corp. in Vancouver, Canada, this revolutionary product has been certified in an independent sample laboratory test at the Antiviral Institute at Utah State University to effectively kill 99.9% of the coronavirus.
In addition to being effective against novel viruses, the
product is also effective against other respiratory viruses, including H1N1, human rhinovirus (HRV)-14 and respiratory syncytial virus (RSV).
*Result shown in lab studies against viruses like SARS-CoV-2.
Nitric Oxide(NO) - NO kills Virus
SaNOtize has developed a proprietary method to effectively deliver Nitric Oxide to the site of an infection. Nitric oxide (NO) has been shown to be effective as an antiviral, antibacterial, anti fungal, and also enhances wound healing. The historical challenge has been how to deliver NO effectively since it is a gas molecule. The company has successfully solved the delivery issue, and now has a true platform technology for upper respiratory and topical dermal infections. The pharmacology, toxicity, and safety data for NO in humans is well established. The NO produced from NORSTM is an identical molecule to nitric oxide naturally produced by the human body, and to the nitric oxide that has a drug approval by the FDA for the treatment of premature infants with acute pulmonary hypertension. There is no biochemical, pharmacokinetic or physical difference between them.
Exclusively Marketed by:
Chemill Pharma Ltd. Kowloon, Hong Kong
Under Technical Collaboration with:
Sanotize Research and Development Corp. Canada
Glenmark Pharmaceuticals Ltd. India Stock: GLKQY.US
Chemill Pharma Limited
Phone : +852 2191 9580
Email : email@example.com
Office：Rm 1907-08, 19/F, SOLO, 83 Bedford Road, Kowloon, Hong Kong
Website : www.chemillpharma.com